Cannabix Marijuana Breath Test Clears Key Regulatory Milestone: Handheld Breath Collection Unit (BCU) Passes FCC Electronic Emissions Testing

Rhea-AI Summary

Cannabix Technologies (OTCID: BLOZF) announced that its handheld Breath Collection Unit (BCU) passed electronic emissions testing required by the US Federal Communications Commission (FCC) and Canada’s ISED standard ICES-003 Issue 7. Cannabix received an ISO/IEC 17025 accredited test report after testing at QAI Laboratories in British Columbia. The BCU and proprietary Breath Cartridges form the core of the Marijuana Breath Test (MBT) system, which aims to collect stable breath samples for analysis by LC-MS. Cannabix said this emissions clearance is a key regulatory milestone toward commercialization in the US and Canada.

Positive

• BCU passed FCC Part 15 electronic emissions testing
• Testing completed to ICES-003 Issue 7 Canadian standard
• Received ISO/IEC 17025 accredited test report
• Testing performed at QAI Laboratories (FCC TCB-designated lab)

Negative

• Additional regulatory steps remain before full commercialization
• No market authorization date or sales approval announced

News Market Reaction

-0.03%

1 alert

-0.03% News Effect

On the day this news was published, BLOZF declined 0.03%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

FCC standard: CFR Title 47 FCC Part 15 Canadian standard: ICES-003 Issue 7 Lab accreditation: ISO/IEC 17025 +1 more

4 metrics

FCC standard CFR Title 47 FCC Part 15 Electronic emissions testing standard for U.S. market

Canadian standard ICES-003 Issue 7 Electronic device emissions standard in Canada

Lab accreditation ISO/IEC 17025 Accredited test report for emissions compliance

Omega experience 25 years Omega Laboratories’ history in forensic drug testing

Market Reality Check

Price: $0.4472 Vol: Volume 89,856 is at 0.82x...

normal vol

$0.4472 Last Close

Volume Volume 89,856 is at 0.82x the 20-day average, indicating subdued trading interest. normal

Technical Shares at $0.356 are trading below the 200-day MA at $0.41, reflecting a still-weak longer-term trend.

Peers on Argus

While BLOZF was unchanged (0%), key peers like ACIXF (-18.39%), RDGL (-8.45%), a...

While BLOZF was unchanged (0%), key peers like ACIXF (-18.39%), RDGL (-8.45%), and PETV (-12.5%) showed notable declines, pointing to stock-specific rather than sector-driven dynamics.

Historical Context

5 past events · Latest: Dec 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 09	Regulatory milestone	Positive	-0.0%	FCC and Canadian emissions testing clearance for Marijuana Breath Test BCU.
Dec 02	Commercial order	Positive	-4.0%	Second BreathLogix alcohol screening unit order from existing maritime customer.
Oct 27	Patent grant	Positive	+0.9%	USPTO patent for contact-free breath analysis device and method.
Oct 16	Device delivery	Positive	+2.6%	Delivery of BreathLogix alcohol screening device to oilfield transport firm.
Sep 30	First product sale	Positive	+16.8%	First sale of BreathLogix unmanned alcohol screening to European maritime customer.

Pattern Detected

Positive operational and regulatory updates often saw aligned price gains, but the latest regulatory milestone drew a flat reaction, extending a mixed pattern.

Recent Company History

This announcement adds another step in Cannabix’s effort to commercialize breath-based testing devices in the U.S. and Canada. Recent news over the past few months featured commercial wins for the BreathLogix alcohol screening platform, including a first maritime sale on Sep 30, 2025 and follow-on orders, alongside a USPTO patent grant on Oct 27, 2025. Those events sometimes triggered meaningful upside, such as a 16.78% move after the first maritime sale, while other positive updates produced modest or negative reactions.

Market Pulse Summary

This announcement marked a key regulatory step, with the Marijuana Breath Test Breath Collection Uni...

Analysis

This announcement marked a key regulatory step, with the Marijuana Breath Test Breath Collection Unit passing FCC and Canadian emissions standards and receiving an ISO/IEC 17025 accredited test report. It advanced Cannabix’s efforts to commercialize breath-based marijuana detection in the U.S. and Canada, alongside an existing partnership with Omega Laboratories, a forensic testing specialist with over 25 years of experience. Investors may watch for further regulatory clearances, commercialization updates, and additional customer deployments as indicators of progress.

Key Terms

federal communications commission (fcc), radio frequency (rf) energy, iso/iec 17025, cfr title 47 fcc part 15, +4 more

8 terms

federal communications commission (fcc) regulatory

"passed electronic emissions testing required by the Federal Communications Commission (FCC)"

A U.S. government agency that acts like a traffic cop for airwaves and communications services, overseeing radio, television, cable, satellite, and certain aspects of internet and wireless spectrum. Its rules, licenses and enforcement actions shape which companies can operate, how much spectrum they can use, and what services they may offer — outcomes that directly affect revenues, costs, competitive advantage and regulatory risk for investors in communications and media businesses.

radio frequency (rf) energy technical

"devices—primarily those that emit radio frequency (RF) energy—before they can be marketed"

Radio frequency (RF) energy is a form of invisible electromagnetic waves—like a focused radio or microwave—that can carry signals or deliver controlled heat to tissue in medical devices. Investors should care because RF energy determines how products perform, how they are regulated and cleared for use, and how they compete on safety, effectiveness and interference with other devices—factors that directly affect market acceptance, liability and revenue potential.

iso/iec 17025 technical

"Cannabix has received an ISO/IEC 17025 accredited test report confirming compliance"

An internationally recognized accreditation for testing and calibration laboratories that confirms they produce reliable, traceable results and follow consistent quality controls. Think of it like a professional license for labs: it shows their methods, equipment and staff competence meet independent standards, which matters to investors because accredited test data lowers technical and regulatory risk, supports product claims, and can speed approvals, supplier selection, and market trust.

cfr title 47 fcc part 15 regulatory

"conducted in accordance with CFR Title 47 FCC Part 15 for the U.S. market"

A section of U.S. federal rules that sets limits and testing requirements for electronic devices that emit radio signals, like Wi‑Fi routers, Bluetooth gadgets, and many consumer electronics, to prevent harmful interference with other communications. For investors, compliance is like having a safety inspection: products that meet these rules can be sold and avoid costly recalls, fines, or blocked market access, while noncompliance can damage revenue and reputation.

ices-003 regulatory

"testing was completed in conformance with ICES-003 Issue 7, the Canadian standard"

ICES-003 is a Canadian technical standard that sets limits on the electromagnetic noise that digital equipment can emit so it does not interfere with radio, cellular and broadcast signals. For investors, it matters because products that fail this test cannot be legally sold or may need redesign, re-testing or recalls, which can delay launches, raise costs and affect revenue — similar to needing a safety certificate before selling a household appliance.

innovation, science and economic development canada (ised) regulatory

"standard for electronic devices published by Innovation, Science and Economic Development Canada (ISED)"

A federal Canadian department that designs and enforces national policy and programs affecting industry, science, technology and economic growth. Think of it as the government’s business toolkit: it hands out research and innovation funding, sets rules for telecommunications and digital infrastructure, and manages programs that affect market access and competitiveness. Investors watch its decisions because grants, regulatory choices and spectrum or licensing rulings can change a company’s costs, growth opportunities and competitive position.

liquid chromatography-mass spectrometry (lc-ms) medical

"for analysis using gold-standard liquid chromatography-mass spectrometry (LC-MS) methods"

An analytical lab technique that first separates a mixture into its components (like passing a soup through finer and finer sieves) and then measures each component’s unique mass signature (like taking a molecular fingerprint). Investors care because LC-MS is a primary tool for verifying drug purity, detecting trace contaminants, measuring biomarker levels in trials, and supporting regulatory filings—results that affect a product’s safety, approval prospects, and commercial value.

telecommunication certification body (tcb) regulatory

"QAI has Telecommunication Certification Body (TCB) designation by the FCC"

A telecommunication certification body (TCB) is an accredited organization authorized to test and approve telecom and wireless equipment against government technical, interference and safety rules, much like a licensed inspector signs off that a new appliance is safe and fits local wiring standards. For investors, TCB approval is a practical gatekeeper to market access and revenue: lacking certification can delay sales, add costs or create regulatory risk, while timely approvals speed product launch and reduce compliance uncertainty.

AI-generated analysis. Not financial advice.

VANCOUVER, British Columbia, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) is pleased to announce that the Cannabix Breath Collection Unit (BCU) has successfully passed electronic emissions testing required by the Federal Communications Commission (FCC). The handheld BCU (Figures 1 and 2) along with Cannabix’s proprietary Breath Cartridges, forms the core hardware of the Marijuana Breath Test (MBT) system. Cannabix is completing the necessary regulatory steps required for the US and Canadian markets. Completion of emissions testing is a key milestone towards commercialization.

Highlights:

• The BCU has achieved a key step by passing US and Canadian electronic emissions testing standards for this innovative device.
• Cannabix MBT provides the ability to collect a stable breath sample to test for the recent use of marijuana.
• Engineering work over recent months and device design updates have focussed on meeting compliance requirements for anticipated commercialization.
  

Electronic emissions testing is required by the FCC for certain electronic devices—primarily those that emit radio frequency (RF) energy—before they can be marketed or sold in the United States. Cannabix has received an ISO/IEC 17025 accredited test report confirming compliance with electronic emissions standards.

The electronic emissions testing for the Cannabix BCU was conducted in accordance with CFR Title 47 FCC Part 15 for the U.S. market. Additionally, testing was completed in conformance with ICES-003 Issue 7, the Canadian standard for electronic devices published by Innovation, Science and Economic Development Canada (ISED). Similar to the FCC in the United States, ISED sets limits and measurement methods for RF emissions and administrative requirements for electronic devices sold or used in Canada.

Testing was performed at QAI Laboratories in British Columbia. QAI has Telecommunication Certification Body (TCB) designation by the FCC and is an ISO/IEC 17025 accredited lab recognized in both the U.S. and Canada for electrical safety evaluations and certification.

The Marijuana Breath Test (MBT) system incorporates Cannabix’s proprietary Breath Collection Unit and Breath Cartridge technologies, designed to collect and preserve breath samples for analysis using gold-standard liquid chromatography-mass spectrometry (LC-MS) methods. Cannabix has a strategic partnership with Omega Laboratories Inc, a global leader in forensic drug testing for over 25 years. Omega holds multiple federal and international certifications and operates a world-class facility with extensive experience in novel drug detection technologies. Together, Cannabix and Omega are advancing the commercialization of the MBT system for customers in the U.S. and Canada.

Figure 1. Cannabix Marijuana Breath Test hardware including Breath Collection Unit (BCU) and Breath Cartridge (BC) technologies.

Figure 2. Cannabix Marijuana Breath Test hardware with Breath Collection Unit (BCU) taking a breath sample.

About Cannabix Technologies Inc.

Cannabix Technologies Inc. is a developer of marijuana and alcohol breath technologies for workplaces, law enforcement and other settings. Breath testing for delta-9 THC (the primary psychoactive ingredient in cannabis) focuses on recent marijuana use. Cannabix is the developer of the BreathLogix autonomous alcohol screening device for organizations who strive to improve alcohol safety and monitoring

We seek Safe Harbor.

On behalf of the Board of Directors

“Rav Mlait”

CEO
Cannabix Technologies Inc.

For further information, contact the Company at info@cannabixtechnologies.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements

This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates," "plan," "continue," "expect," "project," "intend," "believe," "anticipate," "estimate," "may," "will," "potential," "proposed," "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to, statements relating to regulatory testing described in this news release; final development of a commercial or prototype product(s); the successful trial or pilot of company technologies; the commercialization of the Company's products; the negotiation and potential entry into additional agreements with distributors; and the completion of future financings. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information. Important factors that could cause actual results to differ materially from those expressed in the forward-looking information include (but are note limited to): adverse market conditions; risks regarding protection of proprietary technology; the ability of the Company to complete future financings; the ability of the Company to develop and market its future product; risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition; that patent applications are not awarded by regulatory authorities; that the CSE may not approve the issuance of the securities; that the Company’s development of breathalyzer technology will provide any benefit to the Company; there is no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials; there is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies; there is no assurance that any “patent pending” or “provisional patents” technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities; the Company is not currently selling the “MBT” and there is no assurance that the Company ever will; and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/df3ae734-47fb-4ce2-9bc3-a809f997ed51

https://www.globenewswire.com/NewsRoom/AttachmentNg/32b6af10-2937-4e2d-a57d-0e12aad1d358

FAQ

What regulatory test did Cannabix (BLOZF) recently pass on December 9, 2025?

Cannabix reported the BCU passed electronic emissions testing in accordance with CFR Title 47 FCC Part 15 and Canadian ICES-003 Issue 7 standards.

Does the FCC emissions clearance allow immediate US sales of Cannabix MBT (BLOZF)?

No; emissions clearance is a key regulatory milestone but additional regulatory steps are required before full commercialization.

Which lab conducted the emissions testing for Cannabix (BLOZF)?

Testing was performed at QAI Laboratories in British Columbia, a lab with FCC TCB designation and ISO/IEC 17025 accreditation.

What does the Cannabix Marijuana Breath Test (MBT) system use to analyze samples?

The MBT system uses the BCU and Breath Cartridges to collect breath samples for analysis by liquid chromatography-mass spectrometry (LC-MS).

Will the Cannabix MBT (BLOZF) be marketed in Canada after passing ICES-003 testing?

Passing ICES-003 is required for Canadian electronic devices, but Cannabix indicated it is still completing necessary regulatory steps before commercialization.

Does Cannabix (BLOZF) have partners for sample analysis or commercialization?

Yes; Cannabix described a strategic partnership with Omega Laboratories Inc for forensic drug testing and commercialization support.